Literature DB >> 17903813

Activated protein C resistance in patients with arterial ischemic stroke.

R C Rey1, G de Larrañaga, S Lepera, M Cohen, G Saposnik, B Alonso, R E Sica.   

Abstract

BACKGROUND: Activated C protein resistance (APC-R) has recently been reported to be a common cause of thrombophilia; it may be acquired or caused by a genetic defect (factor V Leiden mutation). It is clear that there is an association between APC-R and venous thrombosis. It has been suggested that there is a possible relationship of APC-R with arterial ischemic stroke (IS), but case-control studies have not given enough clues for considering APC-R as a main risk factor.
OBJECTIVES: To assess the incidence of APC-R in patients with IS of several ethiologies in Buenos Aires. PATIENTS AND METHODS: Seventy-two patients with IS were assessed for signs or symptoms of previous clinical thrombophilia and the presence of vascular risk factors (RF). They were searched for APC-R (COATEST, APC resistance-V, with a predilution of the samples) test. Determinations were carried out between 1 to 4 months after the ischemic episode. The plasma of 50 healthy control subjects (blood donors) was used as controls.
RESULTS: None of the patients had signs of previous thrombophilia; 57 (79.2%) had RF for IS, and 3 (4.2%) had APC-R (all of them with RF). One subject in the control group (2%) showed a low APC response (1/50). The occurrence of APC-R among patients with stroke was not significantly higher when compared with the occurrence of APC-R among the control subjects.
CONCLUSIONS: In the present series, the incidence of factor V Leiden related APC-R in the group with IS was similar to the healthy population. Other risk factors were associated in patients showing APC-R.

Entities:  

Year:  2001        PMID: 17903813     DOI: 10.1053/jscd.2001.25464

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  2 in total

1.  Activated Protein C Resistance Does Not Increase Risk for Recurrent Stroke or Death in Stroke Patients.

Authors:  Markus Alexander Thaler; Regina Feurer; Christoph Thaler; Natalie Sonntag; Michael Schleef; Ina-Christine Rondak; Holger Poppert
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

2.  Postmenopausal Hormone Therapy and Risk of Stroke: Impact of the Route of Estrogen Administration and Type of Progestogen.

Authors:  Marianne Canonico; Laure Carcaillon; Geneviève Plu-Bureau; Emmanuel Oger; Archana Singh-Manoux; Pascale Tubert-Bitter; Alexis Elbaz; Pierre-Yves Scarabin
Journal:  Stroke       Date:  2016-06-02       Impact factor: 7.914

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.